Christine M Gronseth1, Scott E McElhone1, Barry E Storer2, Kathleen A Kroeger1, Vicky Sandhu3, Matthew L Fero3,4,5, Frederick R Appelbaum3,4,5, Elihu H Estey3,4,5, Min Fang3,6,5. 1. Cytogenetics Department, Seattle Cancer Care Alliance, Seattle, Washington. 2. Clinical Statistics Department, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Department of Medicine, University of Washington, Seattle, Washington. 5. Seattle Cancer Care Alliance, Seattle, Washington. 6. Department of Pathology, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Chromosomal abnormalities are important in the diagnosis and prognosis of patients with acute myeloid leukemia (AML). Genomic microarray techniques detect recurrent copy-neutral loss of heterozygosity (cnLOH) in addition to copy number aberrations. However, the clinical utility has not been fully established. Therefore, in the current study, the authors examined the prognostic impact of acquired cnLOH in patients with AML, including complete remission (CR) rate, duration of CR, and overall survival (OS). METHODS: A total of 112 consecutive patients with AML who were undergoing chromosome genomic array testing (CGAT) at the Seattle Cancer Care Alliance were included in the current study. DNA from the bone marrow or blood was analyzed with a microarray platform with both single-nucleotide polymorphism (SNP) probes and non-SNP probes to identify acquired cnLOH. Results were correlated with cytogenetic, molecular, immunophenotypic, and other clinicopathological findings. RESULTS: Patients with cnLOH demonstrated a shorter duration of CR (hazard ratio, 1.87; P =.04) and worse OS (HR, 1.82; P = .03). Multivariate analyses confirmed the independent predictive value of cnLOH for early disease recurrence (P =.02). These results largely reflected those in patients with intermediate and unfavorable cytogenetics. Most strikingly, 13q cnLOH was found to demonstrate a 6.64-fold higher rate of disease recurrence (P =.006) and 3.45-fold worse OS (P = .02) and was enriched with the FLT3-ITD (Fms-related tyrosine kinase 3-internal tandem duplication) mutation. CONCLUSIONS: CnLOH has important prognostic significance in patients with AML. CGAT can replace imbalance fluorescence in situ hybridization and the authors recommend the routine use of CGAT to detect cnLOH, particularly among patients with intermediate-risk cytogenetics.
BACKGROUND:Chromosomal abnormalities are important in the diagnosis and prognosis of patients with acute myeloid leukemia (AML). Genomic microarray techniques detect recurrent copy-neutral loss of heterozygosity (cnLOH) in addition to copy number aberrations. However, the clinical utility has not been fully established. Therefore, in the current study, the authors examined the prognostic impact of acquired cnLOH in patients with AML, including complete remission (CR) rate, duration of CR, and overall survival (OS). METHODS: A total of 112 consecutive patients with AML who were undergoing chromosome genomic array testing (CGAT) at the Seattle Cancer Care Alliance were included in the current study. DNA from the bone marrow or blood was analyzed with a microarray platform with both single-nucleotide polymorphism (SNP) probes and non-SNP probes to identify acquired cnLOH. Results were correlated with cytogenetic, molecular, immunophenotypic, and other clinicopathological findings. RESULTS:Patients with cnLOH demonstrated a shorter duration of CR (hazard ratio, 1.87; P =.04) and worse OS (HR, 1.82; P = .03). Multivariate analyses confirmed the independent predictive value of cnLOH for early disease recurrence (P =.02). These results largely reflected those in patients with intermediate and unfavorable cytogenetics. Most strikingly, 13q cnLOH was found to demonstrate a 6.64-fold higher rate of disease recurrence (P =.006) and 3.45-fold worse OS (P = .02) and was enriched with the FLT3-ITD (Fms-related tyrosine kinase 3-internal tandem duplication) mutation. CONCLUSIONS: CnLOH has important prognostic significance in patients with AML. CGAT can replace imbalance fluorescence in situ hybridization and the authors recommend the routine use of CGAT to detect cnLOH, particularly among patients with intermediate-risk cytogenetics.
Authors: Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield Journal: Clin Cancer Res Date: 2019-08-02 Impact factor: 12.531
Authors: Zachary L Skidmore; Alex H Wagner; Robert Lesurf; Katie M Campbell; Jason Kunisaki; Obi L Griffith; Malachi Griffith Journal: Bioinformatics Date: 2016-06-10 Impact factor: 6.937
Authors: Elisabeth K M Mack; André Marquardt; Danny Langer; Petra Ross; Alfred Ultsch; Michael G Kiehl; Hildegard I D Mack; Torsten Haferlach; Andreas Neubauer; Cornelia Brendel Journal: Haematologica Date: 2018-09-06 Impact factor: 9.941
Authors: Eva-Maria Dauber; Wolfgang R Mayr; Hein Hustinx; Marlies Schönbacher; Holger Budde; Tobias J Legler; Margit König; Oskar A Haas; Gerhard Fritsch; Günther F Körmöczi Journal: Haematologica Date: 2018-09-20 Impact factor: 9.941
Authors: Youjin Wang; Weiyin Zhou; Lisa J McReynolds; Hormuzd A Katki; Elizabeth A Griffiths; Swapna Thota; Mitchell J Machiela; Meredith Yeager; Philip McCarthy; Marcelo Pasquini; Junke Wang; Ezgi Karaesmen; Abbas Rizvi; Leah Preus; Hancong Tang; Yiwen Wang; Loreall Pooler; Xin Sheng; Christopher A Haiman; David Van Den Berg; Stephen R Spellman; Tao Wang; Michelle Kuxhausen; Stephen J Chanock; Stephanie J Lee; Theresa E Hahn; Lara E Sucheston-Campbell; Shahinaz M Gadalla Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.996
Authors: Thomas McKerrell; Thaidy Moreno; Hannes Ponstingl; Niccolo Bolli; João M L Dias; German Tischler; Vincenza Colonna; Bridget Manasse; Anthony Bench; David Bloxham; Bram Herman; Danielle Fletcher; Naomi Park; Michael A Quail; Nicla Manes; Clare Hodkinson; Joanna Baxter; Jorge Sierra; Theodora Foukaneli; Alan J Warren; Jianxiang Chi; Paul Costeas; Roland Rad; Brian Huntly; Carolyn Grove; Zemin Ning; Chris Tyler-Smith; Ignacio Varela; Mike Scott; Josep Nomdedeu; Ville Mustonen; George S Vassiliou Journal: Blood Date: 2016-04-27 Impact factor: 25.476